Sign in
CompletedPhase 3

GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

Key facts

Who runs it
Nationwide Children's Hospital
Where
Ann Arbor, Aurora, Charleston, Cleveland, Columbus, Detroit, Durham, Hershey, Houston, Kansas City, Little Rock, Los Angeles, Milwaukee, Minneapolis, Oakland, Orange, Philadelphia, Pittsburgh, Richmond, Sacramento, Salt Lake City, San Antonio, San Francisco, and Washington D.C., United StatesSee the 25 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
141 people enrolled
Started
14 Jun 2022
Ended
10 Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • GM-CSF
  • Placebo
Record updated
9 April 2026

Who can take part

Age
1 day to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • ≥ 40 weeks corrected gestational age to < 18 years; AND
  • Admission to the PICU or CICU; AND
  • Onset of ≥ 2 new organ dysfunctions within the last 3 calendar days (compared to pre-sepsis baseline) as measured by the modified Proulx criteria; AND
  • Documented or suspected infection as the MODS inciting event

Who cannot take part

  • Current or prior diagnosis of hemophagocytic lymphohistiocytosis or macrophage activation syndrome; OR
  • Receipt of anakinra or GM-CSF within the previous 28 days; OR
  • Previous enrollment in the GRACE-2 study
  • Moribund condition in which the patient is unlikely to survive the next 48 hours in opinion of the clinical team; OR
  • History of myeloid leukemia, myelodysplasia, or autoimmune thrombocytopenia; OR
  • Known allergy to GM-CSF; OR
  • Peripheral white blood cell count < 1,000 cells/mm3 as the result of myeloablative therapy OR receipt of myeloablative therapy within the previous 14 days; OR
  • Weight <3kg; OR
  • Limitation of care order at the time of screening; OR
  • Patients at high likelihood of progression to brain death in opinion of the clinical team; OR
  • Known pregnancy; OR
  • Lactating females; OR
  • Resolution of MODS by MODS Day 2; OR

Where in United States

  • CS Mott Children's HospitalAnn Arbor, United States
  • Children's Hospital ColoradoAurora, United States
  • Medical University of South CarolinaCharleston, United States
  • Rainbow Babies and Children's HospitalCleveland, United States
  • Nationwide Children's HospitalColumbus, United States
  • Children's Hospital of MichiganDetroit, United States
  • Duke UniversityDurham, United States
  • Pennsylvania State UniversityHershey, United States
  • Texas Children's HospitalHouston, United States
  • Mercy Children's HospitalKansas City, United States
  • Arkansas Children's HospitalLittle Rock, United States
  • Children's Hospital of Los AngelesLos Angeles, United States
  • Medical College of WisconsinMilwaukee, United States
  • Children's Hospital of MinnesotaMinneapolis, United States
  • University of MinnesotaMinneapolis, United States
  • Benioff Children's Hospital - OaklandOakland, United States
  • Children's Hospital of Orange CountyOrange, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • Children's Hospital of PittsburghPittsburgh, United States
  • Virginia Commonwealth UniversityRichmond, United States
  • University of California - DavisSacramento, United States
  • Primary Children's HospitalSalt Lake City, United States
  • Children's Hospital of San AntonioSan Antonio, United States
  • Benioff Children's Hospital - Mission BaySan Francisco, United States
  • Children's National Medical CenterWashington D.C., United States

About the trial

What the trial wants to find out

The GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.

The 2 groups in the trial

  • GM-CSFExisting treatment, for comparison

    Intravenous GM-CSF 125 mcg/m2/day x 7 days

  • PlaceboPlacebo, for comparison

    Intravenous placebo x 7 days

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
9 April 2026